FANS: Functional analysis of novel SNPs and mutations in human and mouse genomes

National Genotyping Center, Academia Sinica, Taipei, Taiwan 11529, R.O.C.
BMC Bioinformatics (Impact Factor: 2.58). 02/2008; 9 Suppl 12(Suppl 12):S10. DOI: 10.1186/1471-2105-9-S12-S10
Source: PubMed


With the flood of information generated by the new generation of sequencing technologies, more efficient bioinformatics tools are needed for in-depth impact analysis of novel genomic variations. FANS (Functional Analysis of Novel SNPs) was developed to streamline comprehensive but tedious functional analysis steps into a few clicks and to offer a carefully designed presentation of results so researchers can focus more on thinking instead of typing and calculating.
FANS harnesses the power of public information databases and powerful tools from six well established websites to enhance the efficiency of analysis of novel variations. FANS can process any point change in any coding region or GT-AG splice site to provide a clear picture of the disease risk of a prioritized variation by classifying splicing and functional alterations into one of nine risk subtypes with five risk levels.
FANS significantly simplifies the analysis operations to a four-step procedure while still covering all major areas of interest to researchers. FANS offers a convenient way to prioritize the variations and select the ones with most functional impact for validation. Additionally, the program offers a distinct improvement in efficiency over manual operations in our benchmark test.

6 Reads
  • Source
    • "Multiple sequence alignment was performed with the ClustalW software. For predictive analysis of mutation effects, the web-based tool FANS (Functional analysis of novel SNPs and mutations in human and mouse genomes) was used [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Interstitial lung disease occurring in children is a condition characterized by high frequency of cases due to genetic aberrations of pulmonary surfactant homeostasis, that are also believed to be responsible of a fraction of familial pulmonary fibrosis. To our knowledge, ABCA3 gene was not previously reported as causative agent of fibrosis affecting both children and adults in the same kindred. We investigated a large kindred in which two members, a girl whose interstitial lung disease was first recognized at age of 13, and an adult, showed a diffuse pulmonary fibrosis with marked differences in terms of morphology and imaging. An additional, asymptomatic family member was detected by genetic analysis. Surfactant abnormalities were investigated at biochemical, and genetic level, as well as by cell transfection experiments. Bronchoalveolar lavage fluid analysis of the patients revealed absence of surfactant protein C, whereas the gene sequence was normal. By contrast, sequence of the ABCA3 gene showed a novel homozygous G > A transition at nucleotide 2891, localized within exon 21, resulting in a glycine to aspartic acid change at codon 964. Interestingly, the lung specimens from the girl displayed a morphologic usual interstitial pneumonitis-like pattern, whereas the specimens from one of the two adult patients showed rather a non specific interstitial pneumonitis-like pattern. We have detected a large kindred with a novel ABCA3 mutation likely causing interstitial lung fibrosis affecting either young and adult family members. We suggest that ABCA3 gene should be considered in genetic testing in the occurrence of familial pulmonary fibrosis.
    Respiratory research 04/2014; 15(1):43. DOI:10.1186/1465-9921-15-43 · 3.09 Impact Factor
  • Source
    • "The novel SNPs were assessed for functional significance with the Functional Analysis of Novel SNPs (FANS) program ( [16] and ESE finder v3.0. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background This study investigated variation in NR1I2 and NR1I3 and its effect on plasma efavirenz levels in HIV/AIDS patients. Variability in plasma drug levels has largely led research on identifying causative variants in drug metabolising enzyme (DME) genes, with little focus on the nuclear receptor genes NR1I2 and NR1I3, coding for PXR and CAR, respectively, that are involved in regulating DMEs. Methods 464 Bantu-speaking South Africans comprising of HIV/AIDS patients on efavirenz-based treatment (n=301) and 163 healthy subjects were genotyped for 6 SNPs in NR1I2 and NR1I3. 32 of the 301 patients had their DNA binding domains (DBDs) in NR1I2 and NR1I3 sequenced. Results Significantly decreased efavirenz plasma concentrations were observed in patients carrying the NR1I3 rs3003596C/C and T/C genotypes (P=0.015 and P=0.010, respectively). Sequencing resulted in the discovery of a further 13 SNPs, 3 of which are novel variants in the DBD of NR1I2. There were significant differences in the distribution of NR1I2 and NR1I3 SNPs between South Africans when compared to Caucasian, Asian and Yoruba population groups. Conclusion For the realisation of personalised medicine, PXR and CAR genetic variation should be taken into consideration because of their involvement in the regulation of DMEs.
    BMC Medical Genetics 11/2012; 13(1):112. DOI:10.1186/1471-2350-13-112 · 2.08 Impact Factor
  • Source
    • "In contrast to GenoWatch annotating only known SNPs, VarioWatch analyzes both known SNPs and novel variants. By incorporating features similar to FANS (16), VarioWatch investigates a novel variant with its genomic context, analyzes the functional effect if it is located in a protein coding region or in a GT-AG splice site, presents information of genes nearby, checks affection to ESE and ESS hexamers pattern [from Rescue-ESE (17) and Fas-ESS (18)] if the variant is in an exon, and predicts risk of the variant based on the above-mentioned information. If the variant is reported in dbSNP or 1000 Genomes Project (19), related details will be listed as well. "
    [Show abstract] [Hide abstract]
    ABSTRACT: VarioWatch ( has been vastly improved since its former publication GenoWatch in the 2008 Web Server Issue. It is now at least 10 000-times faster in annotating a variant. Drastic speed increase, through complete re-design of its working mechanism, makes VarioWatch capable of annotating millions of human genomic variants generated from next generation sequencing in minutes, if not seconds. While using MegaQuery of VarioWatch to quickly annotate variants, users can apply various filters to retrieve a subgroup of variants according to the risk levels, interested regions, etc. that satisfy users' requirements. In addition to performance leap, many new features have also been added, such as annotation on novel variants, functional analyses on splice sites and in/dels, detailed variant information in tabulated form, plus a risk level decision tree regarding the analyzed variant. Up to 1000 target variants can be visualized with our carefully designed Genome View, Gene View, Transcript View and Variation View. Two commonly used reference versions, NCBI build 36.3 and NCBI build 37.2, are supported. VarioWatch is unique in its ability to annotate comprehensively and efficiently millions of variants online, immediately delivering the results in real time, plus visualizes up to 1000 annotated variants.
    Nucleic Acids Research 05/2012; 40(Web Server issue):W76-81. DOI:10.1093/nar/gks397 · 9.11 Impact Factor
Show more

Preview (2 Sources)

6 Reads
Available from